Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 1999

View Archived Issues

Intratumoral IFN-gamma via retroviral vector assessed in metastatic melanoma

NIDA study sheds new insight on cocaine addiction process

Phakellistatins 10 and 11 available for licensing from ASU

Neristatin 1 available for licensing from ASU

Bristol-Myers Squibb enters target validation collaboration with Exelixis

Genelabs achieves positive results in pivotal trial of GL-701 for treatment of lupus

FDA gives Vasogen go-ahead for TAA trial

SciClone awarded U.S. patent for hepatitis B combination therapy

Baclofen offers promise in migraine prevention

Bayer licenses novel penem prodrug in phase II testing

Discovery Laboratories reaches first marketing agreement for osteoporosis drug

Preclinical study results support potential of NK1 antagonist in treating micturition disorders

Phase II study evaluating oral levalbuterol now under way in Canada

Screening by Japanese researchers leads to identification of FJ-5002 as potent telomerase inhibitor

Pharmacological profile of FR-145715, a new H2 antagonist, studied using in vitro and in vivo models

FDA accepts IND for ImmunoGen's tumor-activated prodrug

New analgesic/antiinflammatory medicines claimed by Sankyo

TNP-470 evaluated in patients with metastatic renal carcinoma

Cytokine production modulators identified as part of Japanese pharmaceutical collaboration

Leteprinim provides therapeutic benefit in SDAT patients in 28-day study

Antihyperglycemic effects of novel imidazoline derivative investigated

Results of open-label study of topiramate in bipolar disorder justify additional trials

New antitumor antibiotic discovered by Yamanouchi

European researchers describe novel mechanism of action for MPB-07 and MPB-27

MedImmune to acquire U.S. Bioscience

Naphthoquinones from Fuji Photo Film exhibit immunosuppressive and antiarthritic activity

Potentially beneficial cardiovascular effects of raloxifene uncovered

BTS-79018, a potent antipsychotic agent with an improved side effect profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.